# Stereotactic Body Radiotherapy Followed by Tislelizumab Plus Platinum-based Chemotherapy Versus Tislelizumab Plus Platinum-based Chemotherapy as Neoadjuvant The

Source: https://onco.cc/trials/nct06598527/  
OnCo record `nct06598527` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of tislelizumab in lung cancer, run by Yang Hong, now recruiting.

## Summary

Stereotactic Body Radiotherapy Followed by Tislelizumab Plus Platinum-based Chemotherapy Versus Tislelizumab Plus Platinum-based Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Stage II-III Non-small Cell Lung Cancer: A Phase III, Randomized, Multicenter, Prospective Study is a phase 3, randomised interventional study registered as NCT06598527 by Yang Hong, with a registry enrolment figure of 360 participants, started 2024-10-15 and due to reach its primary completion in 2027-01-30. Interventions recorded: Stereotactic body radiotherapy (SBRT); Tislelizumab; Chemotherapy. Conditions listed: Lung Cancer (NSCLC). Primary outcome: event-free survival. Lung eligibility wording from the registry: "Patients with cytologically/histologically diagnosed (by means of percutaneous lung aspiration biopsy, bronchoscopy, mediastinoscopy, etc". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-25
- Also known as: SACTION2401
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT06598527
- Phase: 3
- Setting: Stereotactic Body Radiotherapy Followed by Tislelizumab Plus Platinum-based Chemotherapy Versus Tislelizumab Plus Platinum-based Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Stage II-III Non-small Cell Lung Cancer: A Phase III, Randomized, Multicenter, Prospective Study
- Sponsor: Yang Hong
- Enrolled: 360

## Sources

- ClinicalTrials.gov NCT06598527: https://clinicaltrials.gov/study/NCT06598527

## Connected records

- cancers: [Resectable stage I to III non-small-cell lung cancer](https://onco.cc/cancers/resectable-nsclc/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [SBRT / SABR (stereotactic radiotherapy)](https://onco.cc/technologies/sbrt/)
- drugs: [Tislelizumab](https://onco.cc/drugs/tislelizumab/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06598527.json